Cancer and the chemokine network

Nature Reviews Cancer

Volumn 4, Issue 7, 2004, Pages 540-550

  Balkwill, Fran ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA CHEMOKINE; ANTINEOPLASTIC AGENT; BETA CHEMOKINE; CHEMOKINE; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CCR1; CHEMOKINE RECEPTOR CCR10; CHEMOKINE RECEPTOR CCR3; CHEMOKINE RECEPTOR CCR4; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR6; CHEMOKINE RECEPTOR CCR7; CHEMOKINE RECEPTOR CCR8; CHEMOKINE RECEPTOR CCR9; CHEMOKINE RECEPTOR CXCR1; CHEMOKINE RECEPTOR CXCR3; CHEMOKINE RECEPTOR CXCR4; CXCL1 CHEMOKINE; CXCL2 CHEMOKINE; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEIN PARC; RANTES; SECONDARY LYMPHOID TISSUE CHEMOKINE; STROMAL CELL DERIVED FACTOR 1ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; AUTOIMMUNE DISEASE; CANCER CELL; CANCER GROWTH; CANCER IMMUNOLOGY; CANCER INFILTRATION; HUMAN; HUMAN CELL; IMMUNOMODULATION; INFLAMMATION; LEUKOCYTE; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW;

EID: 3042822267     PISSN: 1474175X     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrc1388     Document Type: Review

References (101)

1. Rossi, D. & Zlotnik, A. The biology of chemokines and their receptors. Annu. Rev. Immunol. 18, 217-242 (2000).
2. Murphy, P. M. et al. International union of pharmacology, XXII. Nomenclature for chemokine receptors. Pharmacol. Rev. 52, 145-176 (2000). An encyclopedic review of the chemokine universe.
3. Zlotnik, A. & Yoshie, O. Chemokines: a new classification system and their role in immunity. Immunity 12, 121-127 (2000).
4. Locati, M. et al. Analysis of the gene expression profile activated by the CC chemokine ligand 5/RANTES and by lipopolysaccharide in human monocytes. J. Immunol. 168, 3557-3562 (2002).
5. Gupta, S. K., Lysko, P. G., Pillarisetti, K., Ohlstein, E. & Stadel, J. M. Chemokine receptors in human endothelial cells. J. Biol. Chem. 273, 4282-4287 (1998).
6. Muller, A. et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 410, 50-56 (2001). Experiments on the involvement of chemokines and their receptors in metastasis.
7. Scotton, C. J., Wilson, J. L. Milliken, D., Stamp, G. & Balkwill, F. R. Epithelial cancer cell migration: a role for chemokine receptors? Cancer Res. 61, 4961-4965 (2001).
8. Balkwill, F. The significance of cancer cell expression of CXCR4. Semin. Cancer Biol. 14, 171-179 (2004).
9. Balkwill, F. Chemokine biology in cancer. Semin. Immunol. 15, 49-55 (2003).
10. Balkwill, F. & Mantovani, A. Inflammation and cancer: back to Virchow. Lancet 357, 539-545 (2001).
11. Brigati, C., Noonan, D. M., Albini, A. & Benelli, R. Tumors and inflammatory infiltrates: friends or foes? Clin. Exp. Metastasis 19, 247-258 (2002).
12. Coussens, L. M. & Werb, Z. Cancer and inflammation. Nature 420, 860-867 (2002).
13. Negus, R. P. M., Stamp, G. W. H., Hadley, J. & Balkwill, F. R. A quantitative assessment of the leukocyte infiltrate in ovarian cancer and its relationship to the expression of C-C chemokines. Am. J. Pathol. 150, 1723-1734 (1997).
14. Pollard, J. W. Tumour-educated macrophages promote tumour progression and metastasis. Nature Rev. Cancer 4. 71-78 (2004).
15. Bottazzi, B. et al. Regulation of the macrophage content of neoplasms by chemoattractants. Science 220, 210-212 (1983).
16. Negus, R. P. M. et al. The detection and localization of monocyte chemoattractant protein-1 (MCP-1) in human ovarian cancer. J. Clin. Invest. 95, 2391-2396 (1995).
17. Milliken, D., Scotton, C., Raju, S., Balkwill, F. & Wilson, J. Analysis of chemokines and chemokine receptor expression in ovarian cancer ascites. Clin. Cancer Res. 8, 1108-1114 (2002).
18. Skinnider, B. F. & Mak, T. W. The role of cytokines in classical Hodgkin lymphoma. Blood 99, 4283-4297 (2002).
19. Scotton, C., Milliken, D., Wilson, J., Raju, S. & Balkwill, F. Analysis of CC chemokine and chemokine receptor expression in solid ovarian tumours. Br. J. Cancer 85, 891-897 (2001).
20. Sica, A. et al. Defective expression of the monocyte chemotactic protein-1 receptor CCR2 in macrophages associated with human ovarian carcinoma. J. Immunol. 164, 733-738 (2000).
21. Grimshaw, M. J. & Balkwill, F. R. Inhibition of monocyte and macrophage chemotaxis by hypoxia and inflammation: a potential mechanism. Eur. J. Immunol. 31, 480-489 (2001).
22. H2 chemoattractant. Blood 92, 4036-4039 (1998).
23. Sica, A. et al. Autocrine production of IL-10 mediates defective IL-12 production and NF-κB activation in tumor-associated macrophages. J. Immunol. 164, 762-767 (2000).
24. H2 polarization by the chemokine monocyte chemoattractant protein-1. Nature 404, 407-411 (2000).
25. Zou, W. et al. Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells. Nature Med. 7, 1339-1346 (2001).
26. Mantovani, A., Sozzani, S., Locati, M., Allavena, P. & Sica, A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 23, 549-555 (2002). Excellent review on macrophages and tumour progression.
27. Robinson, S. C., Scott, K. A. & Balkwill, F. R. Chemokine stimulation of monocyte matrix metalloproteinase-9 requires endogenous TNF-α. Eur. J. Immunol. 32, 404-412 (2002).
28. Bingle, L., Brown, N. J. & Lewis, C. E. The role of tumour associated macrophages in tumour progression: implications for new anticancer therapies. J. Pathol. 196, 254-265 (2002).
29. Mantovani, A., Bottazzi, B., Colotta, F., Sozzani, S. & Ruco, L. The origin and function of tumor-associated macrophages. Immunol. Today 13, 265-270 (1992).
30. Lin, E. Y., Nguyen, A. V., Russell, R. G. & Pollard, J. W. Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J. Exp. Med. 193, 727-739 (2001). Interesting paper indicating that tumour-associated macrophages might aid metastatic spread.
31. Zhang, L. et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 348, 203-213 (2003).
32. + T cells. J. Exp. Med. 197, 1017-1028 (2003).
33. Azenshtein, E. et al. The CC chemokine RANTES in breast carcinoma progression: regulation of expression and potential mechanisms of promalignant activity. Cancer Res. 62, 1093-1102 (2002).
34. Saji, H. et al. Significant correlation of monocyte chemoattractant protein-1 expression with neovascularization and progression of breast carcinoma. Cancer 92, 1085-1091 (2001).
35. Luboshits, G. et al. Elevated expression of the CC chemokine regulated on activation, normal T cell expressed and secreted (RANTES) in advanced breast carcinoma. Cancer Res. 59, 4681-4687 (1999).
36. Ohta, M. et al. Monocyte chemoattractant protein-1 expression correlates with macrophage infiltration and tumor vascularity in human esophageal squamous cell carcinomas. Int. J. Cancer 102, 220-224 (2002).
37. Nesbit, M., Schaider, H., Miller, T. H. & Herlyn, M. Low-level monocyte chemoattractant protein-1 stimulation of monocytes leads to tumour formation in nontumorigenic melanoma cells. J. Immunol. 186, 6483-6490 (2001).
38. Monti, P. et al. The CC chemokine MCP-1/CCL2 in pancreatic cancer progression: regulation of expression and potential mechanisms of antimalignant activity. Cancer Res. 63, 7451-7461 (2003).
39. Moran, C. J. et al. RANTES expression is a predictor of survival in stage I lung adenocarcinoma. Clin. Cancer Res. 8, 3803-3812 (2002).
40. Struyf, S. et al. PARC/CCL18 is a plasma CC chemokine with increased levels in childhood acute lymphoblastic leukemia. Am. J. Pathol, 163, 2065-2075 (2003).
41. Murphy, P. M. Chemokines and molecular basis of cancer metastasis. N. Engl. J. Med. 354, 833-835 (2001).
42. Allavena, P. et al. The chemokine receptor switch paradigm and dendritic cell migration: its significance in tumor tissues. Immunol. Rev. 177, 141-149 (2000).
43. Kijima, T. et al. Regulation of cellular proliferation, cytoskeletal function, and signal transduction through CXCR4 and c-Kit in small cell lung cancer cells. Cancer Res. 62, 6304-6311 (2002).
44. Corcione, A. et al. Stromal cell-derived factor-1 as a chemoattractant for follicular center lymphoma B cells. J. Natl Cancer Inst. 92, 628-635 (2000).
45. Zhou, Y., Larsen, P. H., Hao, C. & Yong, V. W. CXCR4 is a major chemokine receptor on glioma cells and mediates their survival. J. Biol. Chem. 277, 49481-49487 (2002).
46. Koshiba, T. et al. Expression of stromal cell-derived factor 1 and CXCRA ligand receptor system in pancreatic cancer: a possible role for tumor progression. Clin. Cancer Res. 6, 3530-3535 (2000).
47. Scotton, C. J. et al. Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer. Cancer Res. 62, 5930-5938 (2002).
48. Hwang, J. H. et al. CXC chemokine receptor 4 expression and function in human anaplastic thyroid cancer cells. J. Clin. Endocrinol. Metab. 88, 408-416 (2003).
49. Geminder, H. et al. A possible role for CXCR4 and its ligand, the CXC chemokine stromal cell-derived factor-1, in the development of bone marrow metastases and neuroblastoma. J. Immunol. 167, 4747-4757 (2001).
50. Tachibana, K. et al. The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract. Nature 393, 591-594 (1998).
51. Zou, Y.-R., Kottmann, A. H., Kuroda, M., Taniuchi, I. & Littman, D. R. Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature 393, 595-599 (1998).
52. null mice. Leukemia 16, 1992-2003 (2002).
53. Ara, T. et al. A role of CXC chemokine ligand 12/stromal cell-derived factor-1/pre-B cell growth stimulating factor and its receptor CXCR4 in fetal and adult T cell development in vivo. J. Immunol. 170, 4649-4655 (2003).
54. Egawa, T. et al. The earliest stages of B cell development require a chemokine stromal cell-derived factor/pre-B cell growth-stimulating factor. Immunity 15, 323-334 (2001).
55. Sun, Y.-X. et al. Expression of CXCR4 and CXCL12 (SDF-1) in human prostate cancers (PCa) in vivo. J. Cell Biochem. 89, 462-473 (2003). Comprehensive study of CXCR4 expression in one cancer type.
56. Jordan, N. J. et al. Expression of functional CXCR4 chemokine receptors on human colonic epethelial cells. J. Clin. Invest. 104, 1061-1069 (1999).
57. Bachelder, R. E., Wendt, M. A. & Mercurio, A. M., Vascular endothelial growth factor promotes breast carcinoma invasion in an autocrine manner by regulating the chemokine receptor CXCR4. Cancer Res. 62, 7203-7206 (2002).
58. Hall, J. M. & Korach, K. S. Stromal cell-derived factor 1, a novel target of estrogen receptor action, mediates the mitogenic effects of estradiol in ovarian and breast cancer cells. Mol. Endocrinol. 17, 792-803 (2003).
59. Heibig, G. et al. NF-κB promotes breast cancer cell migration and metastasis by inducing the expression of the chemokine receptor CXCR4. J. Biol. Chem. 278, 21631-21638 (2003).
60. Staller, P. et al. Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL. Nature 425, 307-311 (2003). Fascinating observation that VHL mutations upregulate CXCR4 - a genetic explanation for chemokine-receptor expression by tumour cells.
61. Schioppa, T. et al. Regulation of the chemokine receptor CXCR4 by hypoxia. J. Exp. Med. 196, 1391-1402 (2003). This paper complements reference 50. It provides an epigenetic explanation for CXCR4 expression on cancer cells.
62. Libura, J. et al. CXCR4-SDF-1 signaling is active in rhabdomyosarcoma cells and regulates locomotion, chemotaxis, and adhesion. Blood 100, 2597-2606 (2002).
63. Kato, M., Kitayama, J., Kazama, S. & Nagawa, H. Expression pattern of CXC chemokine receptor-4 is correlated with lymph node metastasis in human invasive ductal carcinoma. Breast Cancer Res. 5, 144-150 (2003).
64. Darash-Yahana, M. et al. Human prostate cancer growth, vascularisation and metastasis is stimulated high expression levels of the chemokine receptor CXCR4. Proc. Am. Assoc. Cancer Res. 44, 789 (2003).
65. Murakami, T. et al. Expression of CXC chemokine receptor-4 enhances the pulmonary metastatic potential of mudne B16 melanoma cells. Cancer Res. 62, 7328-7334 (2002).
66. Cardones, A. R., Murakami, T. & Hwang, S. T. CXCR4 enhances adhesion of B16 tumor cells to endothelial cells in vitro and in viva via β-integrin. Cancer Res. 63, 6751-6757 (2003).
67. Kang, Y. et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 3, 537-549 (2003).
68. Phillips, R. J. et al. The stromal derived factor-1/CXCL12-CXC chemokine receptor 4 biological axis in non-small cell lung cancer metastases. Am. J. Respir. Crit. Care Med. 167, 1676-1686 (2003).
69. Barbero, S. et al. Stromal cell-derived factor 1a stimulates human glioblastoma cell growth through the activation of both extracellular signal-regulated kinases 1/2 and Akt. Cancer Res. 63, 1969-1974 (2003).
70. Zeelenberg, I. S., Ruuls-Van Stalle, L. & Roos, E. The chemokine receptor CXCR4 is required for outgrowth of colon carcinoma micrometastases. Cancer Res. 63, 3833-3839 (2003). Shows that cancer cells in which CXCR4 has been downregulated still spread to the lungs but they do not proliferate to form metastatic deposits.
71. Moore, R. et al. Tumour necrosis factor-α deficient mice are resistant to skin carcinogenesis. Nature Med. 5, 828-831 (1999).
72. Szlosarek, P. & Balkwill, F. Tumour necrosis factor-α: a potential target in the therapy of solid tumors. Lancet Oncol. 4, 565-573 (2003).
73. Dick, J. E. & Lapidot, T. Stem cells take a shortcut to the bone marrow. Blood 101, 2901-2902 (2003).
74. Petit, I. et al. G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. Nature Immunol. 3, 687-694 (2002).
75. Levesque, J.-R. Hendy, J., Takamatsu, Y., Simmons, P. J. & Bendall, L. J. Disruption of the CXCR4/CXCL12 chemotactic interaction during hematopoietic stem cell mobilization induced by GCSF or cyclophosphamide. J. Clin. Invest. 111, 187-196 (2003).
76. + stem cell recruitment to the liver. J. Clin. Invest. 112, 160-169 (2003).
77. De Clercq, E. The bicyclam AMD3100 story. Nature Rev. Drug Discov. 2, 581-587 (2003).
78. Liles, W. C. et al. Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood 102, 2728-2730 (2003).
79. Schrader, A. J. et al. CXCRA/CXCL12 expression and signalling in kidney cancer. Br. J. Cancer 86, 1250-1256 (2002).
80. Mashino, K. et al. Expression of chemokine receptor CCR7 is associated with lymph node metastasis of gastric carcinoma. Cancer Res. 62, 2937-2941 (2002).
81. Takanami, I. Overexpression of CCR7 mRNA in nonsmall cell lung cancer: correlation with lymph node metastasis. Int. J. Cancer 105, 186-189 (2003).
82. Ding, Y. et al. Association of CC chemokine receptor 7 with lymph node metastasis of esophageal squamous cell carcinoma. Clin. Cancer Res. 9, 3406-3412 (2003).
83. Till, K. J., Lin, K., Zuzel, M. & Cawley, J. C. The chemokine receptor CCR7 and α4 integrin are important for migration of chronic lymphocytic leukemia cells into lymph nodes. Blood 99, 2977-2984 (2002).
84. + cutaneous T-cell lymphoma. Blood 101, 1487-1493 (2003).
85. Ishida, T et al. Clinical significance of CCR4 expression in adult T-cell leukemia/lymphoma: its close association with skin involvement and unfavorable outcome. Clin. Cancer Res. 9, 3625-3634 (2003).
86. Kleeff, J. et al. Detection and localization of MIP-3α/LARC/Exodus, a macrophage proinflammatory chemokine, and its CCR6 receptor in human pancreatic cancer. Int. J. Cancer 81, 650-657 (1999).
87. Manes, S. et al. CCR5 expression influences the progression of human breast cancer in a p53-dependent manner. J. Exp. Med. 198, 1381-1389 (2003).
88. Dhawan, P. & Richmond, A. Role of CXCL1 in tumorigenesis of melanoma. J. Leukoc. Biol. 72, 9-18 (2002).
89. Yang, T. Y. et al. Transgenic expression of the chemokine receptor encoded by human herpesvirus 8 induces an angioproliferative disease resembling Kaposi's sarcoma. J. Exp. Med. 191, 445-453 (2000).
90. Murakami, T. et al. Immune evasion by murine melanoma mediated through CC chemokine receptor-10. J. Exp. Med. 198, 1337-1347 (2003).
91. Wiley, H. E., Gonzalez, E. B., Maki, S., Wu, M.-T. & Hwang, S. T. Expression of CC chemokine receptor-7 and regional lymph node metastasis of B16 murine melanoma. J. Natl Cancer Inst. 93, 1638-1643 (2001).
92. Proudfoot, A. E. I. Chemokine receptors: multifaceted therapeutic targets. Nature Rev. Immunol. 2, 106-115 (2002).
93. Belperio, J. A. et al. CXC chemokines in angiogenesis. J. Leukoc. Biol. 68, 1-8, (2000).
94. Proudfoot, A. E. et al. Amino-terminally modified RANTES analogues demonstrate differential effects on RANTES receptors. J. Biol. Chem. 274, 32478-32485 (1999).
95. Robinson, S. C. et al. A chemokine receptor antagonist inhibits experimental breast tumor growth. Cancer Res. 63, 8360-8365 (2003). Proof-of-principle study showing that chemokine-receptor antagonists inhibit the macrophage infiltrate in experimental tumours and slow down tumour growth.
96. Zeelenberg, I. S., Ruuls-Van Stalle, L. & Roos, E. Retention of CXCR4 in the endoplasmic reticulum blocks dissemination of a cell hybridoma. J. Clin. Invest. 108, 269-277 (2001).
97. Bertolini, F. et al. CXCR4 neutralization, a novel therapeutic approach for non-Hodgkin's lymphoma. Cancer Res. 62, 3106-3112 (2002).
98. Rubin, J. B. et al. A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors. Proc. Natl Acad. Sci. USA 100, 13513-13518 (2003). Translational study showing that a chemokine-receptor antagonist acts directly on tumour cells to inhibit tumour growth in the brain.
99. Signore, A., Capdotti, G., Scopinaro, F., Bonanno, E. & Modesti, A. Radiolabelled lymphokines and growth factors for in vivo imaging of inflammation, infection and cancer. Trends Immunol, 24, 365-402 (2003).
100. Homey, B., Muller, A. & Zlotnik, A. Chemokines: agents for the immunotherapy of cancer? Nature Rev. Immunol. 2, 175-184 (2002).
101. Reya, T., Morrison, S. J., Clarke, M. F. & Weissman, I. L. Stem cells, cancer, and cancer stem cells. Nature 414, 105-111 (2001).